Get the Stockscreener App
1.75
3.85%
-0.07
After Hours:
1.76
0.01
+0.57%
Metagenomi Inc stock is traded at $1.75, with a volume of 784.38K.
It is down -3.85% in the last 24 hours and down -10.71% over the past month.
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).
See More
Previous Close:
$1.82
Open:
$1.85
24h Volume:
784.38K
Relative Volume:
2.91
Market Cap:
$66.81M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-16.27%
1M Performance:
-10.71%
6M Performance:
-75.00%
1Y Performance:
+0.00%
1-Day Range:
$1.68
$1.85
1-Week Range:
$1.68
$2.34
52-Week Range:
$1.68
$12.74
Metagenomi Inc Stock (MGX) Company Profile
Name
Metagenomi Inc
Sector
Industry
Phone
(510) 871-4880
Address
5959 HORTON STREET, EMERYVILLE
Compare MGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| MGX | 1.75 | 66.81M | 0 | 0 | 0 | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Metagenomi Inc Stock (MGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Initiated | H.C. Wainwright | Buy |
| May-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-05-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-24 | Initiated | Chardan Capital Markets | Buy |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Mar-05-24 | Initiated | Jefferies | Buy |
| Mar-05-24 | Initiated | TD Cowen | Outperform |
| Mar-05-24 | Initiated | Wells Fargo | Overweight |
View All
Metagenomi Inc Stock (MGX) Latest News
Lawsuit filed for Investors who lost money with shares of Metagenomi, Inc. (NASDAQ: MGX) - openPR
MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Fraud Lawsuit - cnhinews.com
METAGENOMI ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi - GlobeNewswire Inc.
Levi & Korsinsky Notifies Shareholders of Metagenomi, Inc. (MGX) of a Class Action Lawsuit and an Upcoming Deadline - GlobeNewswire
MGX Deadline: MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Lawsuit - PR Newswire
What Makes Metagenomi (MGX) a New Buy Stock - Yahoo Finance
Investors who lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class ActionMGX - PR Newswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi - GlobeNewswire
Metagenomi Inc. Class Action: Lead Plaintiff Deadline is November 25, 2024; Contact Robbins LLP for - EIN News
Metagenomi Third Quarter 2024 Earnings: US$0.51 loss per share (vs US$3.33 loss in 3Q 2023) - Simply Wall St
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Metagenomi, Inc.(MGX) Shareholders - PR Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Metagenomi - PR Newswire
SHAREHOLDER ALERT: Holzer & Holzer, LLC Reminds Investors - GlobeNewswire
Investors who lost money on Metagenomi, Inc.(MGX) should contact Levi & Korsinsky about pending Class ActionMGX - GlobeNewswire
Class Action Filed Against Metagenomi, Inc. (MGX) Seeking Recovery for InvestorsContact The Gross Law Firm - PR Newswire
DEADLINE ALERT for MGX, POWW, and FNA: The Law Offices of - GlobeNewswire
Metagenomi reports Q3 EPS (51c), consensus (78c) - TipRanks
Metagenomi: Q3 Earnings Snapshot - San Antonio Express-News
Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results - GlobeNewswire
Metagenomi's MGX-001 Shows Promise in Hemophilia A, Reports $274.6M Cash Position | MGX Stock News - StockTitan
MGX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages - GlobeNewswire
MGX Class Action: Robbins LLP Reminds Stockholders of the Pendin - GuruFocus.com
MGX Class Action: Robbins LLP Reminds Stockholders of the Pending Lead Plaintiff Deadline in the Metagenomi Inc. Class Action and Urges Investors with Large Losses to Seek Counsel - PR Newswire
METAGENOMI, INC. (NASDAQ: MGX) DEADLINE ALERT: Bernstein - GlobeNewswire
METAGENOMI, INC. (NASDAQ: MGX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Metagenomi, Inc. - The Bakersfield Californian
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi LawsuitMGX - PR Newswire
MGX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Metagenomi, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Shareholders that lost money on Metagenomi, Inc.(MGX) should con - GuruFocus.com
Shareholders that lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class ActionMGX - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Metagenomi, Inc.MGX - PR Newswire
Metagenomi, Inc. (NASDAQ:MGX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Brokerages Set Metagenomi, Inc. (NASDAQ:MGX) Price Target at $15.50 - MarketBeat
MGX DEADLINE NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, - GlobeNewswire
Shareholders that lost money on Metagenomi, Inc.(MGX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - The Malaysian Reserve
MGX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Metagenomi, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
J.P. Morgan downgrades Metagenomi over Moderna deal termination - MSN
Shareholders that lost money on Metagenomi, Inc. (MGX) - GlobeNewswire
Metagenomi (NASDAQ:MGX) Shares Up 1.9%Here's Why - MarketBeat
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
November 25, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MGX - GlobeNewswire
Glancy Prongay & Murray LLP Reminds Investors of Looming - GlobeNewswire
Metagenomi To Present New Preclinical Hemophilia A Data at - GlobeNewswire
Metagenomi to Present Breakthrough Hemophilia A Gene Therapy Data at ASH 2024 | MGX Stock News - StockTitan
Investors Who Lost Money With NASDAQ:MGX Shares Should Contact the Shareholders Foundation in Connection With Lawsuit Against Metagenomi, Inc - AccessWire
Metagenomi, Inc. Sued for Securities Law ViolationsInvestors - GuruFocus.com
Metagenomi, Inc. Securities Fraud Class Action Lawsuit - GlobeNewswire
Faruqi & Faruqi Reminds Metagenomi Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 25, 2024MGX - AccessWire
MGX Investors Have Opportunity to Lead Metagenomi, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Metagenomi Inc Stock (MGX) Financials Data
There is no financial data for Metagenomi Inc (MGX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):